XENON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.09 USD | +2.70% |
|
-0.96% | -10.79% |
Financials (USD)
| Sales 2024 * | 2.39M | Sales 2025 * | 9.5M | Capitalization | 3.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -220M | Net income 2025 * | -260M | EV / Sales 2024 * | 1,061 x |
| Net cash position 2024 * | 560M | Net cash position 2025 * | 507M | EV / Sales 2025 * | 273 x |
| P/E ratio 2024 * |
-13.9
x | P/E ratio 2025 * |
-12.3
x | Employees | 255 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xenon Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +2.70% | ||
| 1 week | -0.96% | ||
| Current month | -4.55% | ||
| 1 month | -6.61% | ||
| 3 months | -8.79% | ||
| 6 months | +25.66% | ||
| Current year | -10.79% |
1 week
39.01
41.72
1 month
39.0144.47
Current year
39.0150.99
1 year
27.9950.99
3 years
14.6550.99
5 years
7.0050.99
10 years
2.1050.99
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 13-10-20 |
Simon Pimstone
FOU | Founder | 56 | 96-11-04 |
Sherry Aulin
DFI | Director of Finance/CFO | 40 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20-11-04 |
Mohammad Azab
BRD | Director/Board Member | 68 | 03-09-30 |
Justin Gover
BRD | Director/Board Member | 53 | 23-08-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 16 M€ | -7.93% | ||
| 0.22% | 0 M€ | 0.00% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.20% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 41.09 | +2.70% | 323,512 |
| 24-04-22 | 40.01 | +0.33% | 395,140 |
| 24-04-19 | 39.88 | -1.07% | 362,875 |
| 24-04-18 | 40.31 | -3.17% | 324,121 |
| 24-04-17 | 41.63 | +0.34% | 393,800 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
41.09
USD
Average target price
57.44
USD
Spread / Average Target
+39.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.79% | 3.1B | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +1.66% | 22.19B | |
| -16.16% | 21.33B | |
| -6.82% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- XENE Stock
